Key facts
- This page summarizes Prashant Kohli's Form 4 filing for Grace Therapeutics, Inc. (GRCE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Sep 2026, 07:30.
Prashant Kohli - 09 Sep 2026 Form 4 Insider Report for Grace Therapeutics, Inc. (GRCE)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- GRCE
- Reported as of
- 09 Sep 2026
- Net transaction value
- +$214,000
- SEC form
- 4
- Accepted by SEC
- 10 Sep 2026, 07:30:38 UTC
- Prior SEC filing
- 01 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert DelAversano as attorney-in-fact for Prashant Kohli
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Prashant Kohli filed Form 4 for Grace Therapeutics, Inc. (GRCE) on 10 Sep 2026.
Change
- Previous filing in this sequence was filed on 01 Sep 2026.
- Current net transaction value: +$214,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001946739
Primary reporting owner
Kohli Prashant
- Relationship
- Chief Executive Officer, Director
- Address
- C/O GRACE THERAPEUTICS, INC., 103 CARNEGIE CENTER, SUITE 300, PRINCETON
- Signature
- /s/ Robert DelAversano as attorney-in-fact for Prashant Kohli
- Signature date
- 10 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GRCE
transaction
Common Stock
Purchase
- Transaction value
- $214,000
- Shares
- +100,000
- Change %
- +468%
- Price
- $2.14
- Shares after
- 121,357
- Date
- 09 Sep 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.